Skip to main content

Table 2 Twelve cases with 13 major discrepancies

From: Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience

Case ID Diagnosis Outside lab antibody Laboratory ER NEG/POS (%)a PR NEG/POS (%)a
Outside In-house Outside In-house
1 IDC Unknown International NEG (< 1) NEG (0) NEG (< 1) POS (1)
2 IDC ER-monoclonal mouse antibody, clone ID5-α
PR-monoclonal mouse antibody, clone PgR 636
Reference NEG (0) POS (3) NEG (0) NEG (0)
3 ILC ER-GF11, Leica
PR-1294, DAKO
Community NEG (0) NEG (< 1) NEG (0) POS (11)
4 IDC ER-SP1 monoclonal, Ventana
PR-1E2 monoclonal, Ventana
Community NEG (0) NEG (0) NEG (0) POS (1)
5 IDC ER-SP1 monoclonal, Ventana
PR-1E2 monoclonal, Ventana
Community NEG (0) POS (1) NEG (0) NEG (0)
6 IDC ER-SP1 monoclonal, Ventana
PR-1E2 monoclonal, Ventana
Community NEG (< 1) NEG (0) NEG (< 1) POS (5)
7 IDC Unknown Reference NEG (< 1) POS (2) NEG (0) NEG (0)
8 IDC ER-SP1 monoclonal
PR-1E2 monoclonal
Community NEG (0) NEG (0) NEG (0) POS (2)
9b IDC ER-SP1 monoclonal
PR-1E2 monoclonal
Reference NEG (< 1) POS (2) NEG (< 1) POS (5)
10 IDC ER-Monoclonal 6F11
PR-monoclonal mouse antibody, clone PgR 636
Community NEG (< 1) POS (15) NEG (< 1) NEG (< 1)
11 IDC ER-SP1 monoclonal
PR-1E2 monoclonal
Community NEG (0) NEG (0) NEG (0) POS (5)
12 IDC Unknown International NEG (< 1) NEG (0) NEG (< 1) POS (10)
  1. ER estrogen receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NEG negative, POS positive, PR progesterone receptor
  2. aPercentage of cells that stained for ER or PR
  3. bDiscrepancy in both ER and PR